Skip to main content
. 2016 Mar 8;7(16):21865–21874. doi: 10.18632/oncotarget.7990

Figure 5. Identification of circulating miRNAs as novel biomarkers for detecting metastatic breast cancer.

Figure 5

(A) Heatmap of the circulating miRNA profiling analysis using purified RNAs from three lymph node positive (LN+) and three lymph node negative (LN−), as well as four normal control from age-matched healthy females. Three significantly upregulated circulating miRNAs (miR-20b, miR-106aand miR-16) and four downregulated circulating miRNAs (miR-671, miR-151-3p, miR-433 and miR-409-3p) in breast cancer were identified. (B) The method of plasma-based direct quantification of circulating miRNAs was applied to validate the miRNA signature in A, demonstrating significant upregulation of miR-106a in lymph node positive breast cancer patients compared with normal control.